| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f3166d2820b5872ab84d235e5fae1d45 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-1027
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2827
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6849 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate |
2020-07-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4808c0a37c33b22b45314b8d3bbbc818
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2a8637a268c27e63ad3f6aaf09bf6471
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b53bbcc11a78424b6d9609619105ba48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0bc99cdf8e86bf5f41f0e8e7e4be72e7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d1c9903abf85dea3650fcf7259bdbc15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f1cd298bbae4f57ddef32b65756f70c4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c9aa6e3c138d31b3e2720b10457a4c98
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_145421436b95a4fd9f2ce1ba260e21f1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0a693284f80dfe62f4a7ab0e89722df2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4b69d06042ebc9218c477a50f79b694b |
| publicationDate |
2021-01-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2021005546-A1 |
| titleOfInvention |
Antibodies to human programmed death receptor pd-1 |
| abstract |
The present invention relates to an antibody or antigen-binding portion thereof that can bind to human programmed death 1 (PD-1). The antibody according to the present invention is further used in the preparation of a drug for treating disease in which expression of PD-1 is detrimental. |
| priorityDate |
2019-07-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |